A5030980984- CAR-T cell therapy research
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Biomedical Ethics and Regulation
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Peptidase Inhibition and Analysis
- Virus-based gene therapy research
- Peripheral Neuropathies and Disorders
- Hepatitis B Virus Studies
- Immune cells in cancer
- HER2/EGFR in Cancer Research
- Acute Lymphoblastic Leukemia research
- Myasthenia Gravis and Thymoma
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
- Liver physiology and pathology
- Inflammatory Bowel Disease
- Diet and metabolism studies
- Prostate Cancer Treatment and Research
- Autoimmune Neurological Disorders and Treatments
West German Heart and Vascular Center Essen
2025
University of Duisburg-Essen
2025
Immatics Biotechnologies (Germany)
2013-2023
Essen University Hospital
2007-2021
Celldex Therapeutics (United States)
2013
University of Tübingen
1997-2012
Institute of Biophysics
2012
University of Szeged
2012
The Maria Sklodowska-Curie National Research Institute of Oncology
2012
3D-Micromac (Germany)
2006-2011
Previous attempts have shown the potential of T cells in immunotherapy cancer. Here, we report on clinical activity a bispecific antibody construct called blinatumomab, which has to engage all cytotoxic patients for lysis cancer cells. Doses as low 0.005 milligrams per square meter day non-Hodgkin's lymphoma led an elimination target blood. Partial and complete tumor regressions were first observed at dose level 0.015 milligrams, seven treated 0.06 experienced regression. Blinatumomab also...
Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is member of novel class antibodies that redirect T cells for selective lysis tumor cells. In acute lymphoblastic leukemia (ALL), persistence or relapse minimal residual disease (MRD) after chemotherapy indicates resistance to and results in hematologic relapse. A phase II clinical study was conducted determine efficacy blinatumomab MRD-positive B-lineage ALL.Patients with MRD induction consolidation therapy were...
Abstract Purpose: Immunotherapy for hepatocellular carcinoma (HCC) shows considerable promise in improving clinical outcomes. HepaVac-101 represents a single-arm, first-in-human phase I/II multicenter cancer vaccine trial HCC (NCT03203005). It combines multipeptide antigens (IMA970A) with the TLR7/8/RIG I agonist CV8102. IMA970A includes 5 HLA-A*24 and 7 HLA-A*02 as well 4 HLA-DR restricted peptides selected after mass spectrometric identification human tissues or cell lines. CV8102 is an...
T cell receptor (TCR)-based immunotherapy has emerged as a promising therapeutic approach for the treatment of patients with solid cancers. Identifying peptide-human leukocyte antigen (pHLA) complexes highly presented on tumors and rarely expressed healthy tissue in combination high-affinity TCRs that when introduced into cells can redirect to eliminate tumor but not is key requirement safe efficacious TCR-based therapies. To discover shared antigens could be targeted via adoptive therapy,...
Ziel/Aim: Chimeric antigen receptor (CAR) T-cell therapy has proven highly effective in relapsed and refractory large B-cell lymphomas. Yet, it remains an open question how to identify potential non-responders ahead of treatment further improve their outcome. Several international research groups are currently working on the integration metabolic tumor volume (MTV), measured by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (PET), into newly developed models. Therefore, we...
Abstract Human CTL have been isolated that show self-restricted recognition of autologous lymphoblastoid cell lines and allorecognition. The line ligand most likely used a peptide is expressed in EBV-bearing cells when the virus enters lytic cycle. This presented to CD8+ by HLA-Cw7 molecules. allogeneic recognized on non-EBV-infected composed class I glycoprotein naturally selected self-peptide. In previous studies we demonstrated this determined two MHC-linked genes: one gene encodes...
<i>Background:</i> Rising serum levels of prostate-specific antigen (PSA) after radical prostatectomy are indicative recurrent prostate cancer. This double-blind, placebo-controlled phase II study evaluated the anti-tumour activity anti-epithelial cell adhesion molecule (EpCAM) antibody adecatumumab in delaying biochemical disease progression. <i>Patients and Methods:</i> Prostate cancer patients with increasing PSA following were randomized to low- (2 mg/kg) or...
The development of efficient immunotherapies requires strong rationalization. We have recently implemented a large analysis biomarkers in two studies involving the multi-peptide vaccine IMA901 and advanced renal cell cancer patients. Our findings demonstrate that breadth immune responses was associated with clinical benefits single-dose cyclophosphamide reduced amount regulatory T cells prolonged survival after vaccination.
Abstract IMA101 is an actively personalized, multi-targeted adoptive cell therapy (ACT), whereby autologous T cells are directed against multiple novel defined peptide-HLA (pHLA) cancer targets. HLA-A*02:01-positive patients with relapsed/refractory solid tumors expressing ≥1 of 8 predefined targets underwent leukapheresis. Endogenous specific for up to 4 were primed and expanded in vitro. Patients received lymphodepletion (fludarabine, cyclophosphamide), followed by T-cell infusion low-dose...
The nature of alloantigens seen by T lymphocytes, in particular the role peptides allorecognition, has been studied intensively whereas knowledge about vivo emergence, diversity, and structural basis specificity alloreactive cells is very limited. Here we describe human cell clones that recognize HLA-B35 a peptide-dependent manner. TCR sequence analysis revealed several these allospecific utilize homologous TCR: they all express TCRAV2S3J36C1 TCRBV4S1J2S7C2 chains with highly related CDR3...
4529 Background: IMA901 is a therapeutic cancer vaccine based on the selection of naturally presented tumor-associated peptides (9 HLA-class I- and 1 HLA class II-binding peptides). A previous phase I study showed significant correlation disease control rate (DCR) at 3 mo with T-cell responses to multiple but no vaccinated peptide. Methods: HLA-A*02+ patients clear-cell RCC documented progression during or after first-line cytokine- TKI-based therapy were randomized 1:1 receive up 17...
<h3>Background</h3> Adoptive cell therapy demonstrated significant clinical benefit in patients with hematological malignancies but results most solid tumors have been less encouraging so far. In the IMA203 trial we are treating advanced cancer utilizing TCR-engineered T cells (TCR-T) directed against an HLA-A*02-restricted peptide derived from highly prevalent testis antigen PRAME. This target was selected due to homogenous expression and exceptionally high density per tumor (assessed by...
TPS183 Background: IMA901 is a therapeutic vaccine composed of multiple naturally presented tumor-associated peptides (TUMAPs). Previous data have indicated that vaccination with results in relevant clinical benefit, ie. advanced RCC patients detectable T cell responses against TUMAPs had better disease control and overall survival as compared to without such responses. Furthermore, pre-treatment single dose cyclophosphamide (CY; 300mg/m2) was able reduce regulatory cells (Treg) improve...
T-cell-dependent B-cell help is likely to be of major importance in the pathogenesis myasthenia gravis, but mechanisms provoking a pathological anti-acetylcholine receptor (AChR) response are poorly understood. We report on dysregulation recently identified CD4-/CD8- (double-negative) T cells (DN cells), which have been shown participate immunoregulation and antibody augmentation. Compared with healthy controls, significantly increased frequencies DN were found blood gravis patients...
TPS3135 Background: HCC is the third leading cause of death from cancer globally with an extremely variable 5-year survival rate. The HepaVac-101 phase I/II, first-in-man, therapeutic vaccine single-arm clinical trial performed as part HepaVac project, funded by European Commission's 7th Framework Program under Grant Agreement Nr. 602893 (www.hepavac.eu). identification numbers are NCT03203005 (Clinical trials.gov) and 2015-003389-10 (EudraCT). Methods: IMA970A a multi-peptide-based composed...